Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer

A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer

(2011) Katherine M. Bell-McGuinn et al.   GYNECOLOGIC ONCOLOGY

Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma

(2011) Steven J. O’Day et al.   INVESTIGATIONAL NEW DRUGS

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

(2010) Peter Hersey et al.   CANCER

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds  5 1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

(2008) A. D. Ricart et al.   CLINICAL CANCER RESEARCH

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Response to Combination Celecoxib and Erlotinib Therapy in Non-small Cell Lung Cancer Is Associated with a Low Baseline Matrix Metalloproteinase-9 and a Decline in Serum-Soluble E-Cadherin

(2008) Karen L. Reckamp et al.   Journal of Thoracic Oncology

Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis

(2008) D. Gao et al.   SCIENCE